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Previewsapparent opposing effects of PRMT5
activity on tumorigenesis need further
investigation.
Fourth, the observation of increased
phosphorylation of PRMT5 in CD34+ cells
from one MPN patient without activating
JAK2 mutation suggests that other tyro-
sine kinases could phosphorylate
PRMT5. Will impaired PRMT5 also be
the consequence of uncontrolled activity
of tyrosine kinases, such as mutated
ABL, PDGFR, or FLT3, frequently found
in chronic and acute malignant
myeloproliferations?
Finally, since phosphorylation and inhi-
bition of PRMT5 activity are properties
specific for themutated JAK2 proteins, in-
hibiting the interaction between mutant
JAK2 and PRMT5 could potentially inter-fere with MPN pathogenesis without
affecting the wild-type JAK2.REFERENCES
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Bredel et al. (2010) recently identified a subset of glioblastomas that harbormonoallelic loss ofNFKBIA, which
negatively affects patient prognosis. This finding raises newquestions as to the role of IkBa andNF-kB in glio-
blastoma, the relationship between EGFR and NF-kB signaling, and potential therapeutic targets.When we think of mutations that promote
cancer, those used for textbook and
review examples, the NF-kB pathway
does not get a lot of attention. Yet
NF-kB is clearly established as an impor-
tant mediator of oncogenesis (Karin,
2006), and mutations in the immediate
regulatory pathways leading to NF-kB
activation have been characterized
(Courtois andGilmore, 2006). Importantly,
well-established mutations that lead to
cancer, such as activating mutations in
Ras, function oncogenically through
NF-kB activation (Basse`res et al., 2010;
Mayo et al., 1997; Meylan et al., 2009).
New work from Bredel et al. (2010)
demonstrates a fascinating monoallelicdeletion of NFKBIA, in patient-derived
glioblastoma multiforme (GBM). This
gene encodes IkBa, a critical negative
regulator of canonical NF-kB activation.
The work suggests an interesting link
between EGFR-induced signaling in
GBM and the loss of IkBa.
NF-kB is a transcription factor com-
prised of homo- and heterodimers of
five subunits: p65/RelA, RelB, c-Rel,
p105/p50, and p100/p52. Under basal
conditions, IkB molecules (IkBa, b,
and 3 isoforms) sequester p65- and
c-Rel-containing dimers in the cytoplasm.
Full-length p100 and p105 contain similar
motifs to IkB and must be processed to
yield active p50 and p52 subunits. Uponactivation by cytokines or other stimuli,
the IKK complex phosphorylates IkB,
leading to its proteasomal degradation,
which leaves NF-kB free to accumulate in
the nucleus to control target gene expres-
sion. Genes regulated by NF-kB promote
cell proliferation and survival, underlying
the importance of this transcription factor
both in normal cell responses and in onco-
genesis (Karin, 2006).
Due to the integral involvement of
NF-kB in promoting proliferation and the
survival of cells of the hematopoietic
system, it is not surprising that mutations
in this pathway are observed in hemato-
logic malignancies. c-Rel is often ampli-
fied in B cell malignancies and Hodgkin’sFebruary 15, 2011 ª2011 Elsevier Inc. 163
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Figure 1. Link between EGFR and NF-kB Pathways in Glioblastoma
(A) In a basal setting, neither EGFR nor NF-kB is activated.
(B) In a glioma cell with EGFR amplification, the overexpressed receptor is present on the membrane in
dimers and responds to EGF, ultimately leading to NF-kB activation.
(C) In a glioma cell with NFKBIA deletion, normal EGFR is present, and stimulation by EGF is followed by
NF-kB signaling. In this setting, EGF signaling to NF-kB is proposed to be facilitated by the loss of IkBa,
which may also lead to higher basal NF-kB activity, free NF-kB dimers in the cytoplasm or nucleus, or
compensation by other IkB isoforms. Additionally, the loss of IkBamay negate a potential NF-kB-indepen-
dent mechanism for this inhibitor.
(D) In a glioma cell with EGFRvIII expression, the cell constitutively signals through the EGFR pathway
independent of EGF. It remains to be determined if EGFRvIII can activate NF-kB in a similar manner to
wild-type EGFR. Purple triangles represent EGF, while red receptors represent EGFR.
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Previewslymphoma. Presumably, the abundance
of c-Rel subunits overcomes the inhibi-
tory mechanism of the IkBs, leading to
constitutive activation. In both B cell and
T cell leukemias/lymphomas, p100 trun-
cations eliminate the inhibitory domains
but leave p52 intact, resulting in a weakly
oncogenic NF-kB subunit. The oncopro-
tein BCL-3, an IkB-related NF-kB coacti-
vator that functions with the p50 and
p52 subunits, is involved in the t(14:19)
translocation in B cell CLL, ultimately
increasing BCL-3 expression (Courtois
and Gilmore, 2006). Analysis of multiple
myeloma samples shows increased
NF-kB activity in the majority of patients,
which occurs through alterations to
a number of upstream NF-kB signaling
molecules including BIRC2/3, CYLD,
CD40, NFKB1, NFKB2, NIK, and TRAF3
(Annunziata et al., 2007). NF-kB-related
mutations are not limited to leukemias.
IKK3 is a kinase related to IKKa and b,
typically involved in innate immune
signaling, but it has also been shown to
be capable of canonical NF-kB pathway164 Cancer Cell 19, February 15, 2011 ª2011activation. Amplification of the genomic
locus leading to IKK3 overexpression
has been documented in breast cancer
cell lines and tumor samples (Boehm
et al., 2007). Given the strong evidence
of NF-kB subunits exhibiting oncogenic
activity, it follows that the inhibitory IkBs
would demonstrate tumor suppressor
function. Consistent with this, as many
as 10% of Hodgkin’s lymphoma speci-
mens show inactivation of both alleles of
NFKBIA (Courtois and Gilmore, 2006).
By analyzing a large cohort of human
glioblastomas, Bredel et al. (2010) discov-
ered heterozygous NFKBIA deletions in
almost 25% of tumors. Interestingly, the
loss ofNFKBIA generally does not overlap
with EGFR amplification, one of the most
common genetic alterations in glioblas-
toma. In fact, EGFR-induced signaling is
considered important for most, if not all,
of glioma. Since it has been shown that
EGFR can activate NF-kB, this mutual
exclusivity suggests that EGFR and IkBa
fall in the same pathway. Consistent with
this idea, Bredel et al. (2010) show thatElsevier Inc.both NFKBIA-deleted tumors and EGFR-
amplified tumors have a similar decrease
in patient survival compared with those
that are wild-type for both genes. They
also demonstrate that expressing IkBa
in NFKBIA-deleted or EGFR-amplified
primary cultures decreased their viability,
while cells that were wild-type for both
were unaffected. Work from the Cancer
Genome Atlas project identified four
distinct subtypes in glioma: classical,
mesenchymal, neural, and proneural
(Verhaak et al., 2010). When the distribu-
tion of these two mutations is analyzed
based on tumor subtype, those with
EGFR amplification tend to cluster as
classical, while those with NFKBIA dele-
tion tend to fall into the three nonclassical
subtypes. One interpretation is both of
thesemutationsmay cause NF-kB activa-
tion as a more general feature of GBM,
regardless of subtype (Figure 1). In future
work, novel mutations that affect this
signaling axis to a similar end may be
discovered in tumors that are wild-type
for EGFR and IkBa. On the other hand,
these mutations may have substantially
different effects on the signaling in the
tumor, manifested by the distinct segre-
gation into different subtypes. Further
studies to directly compare EGFR-ampli-
fied samples with NFKBIA-deleted ones
will be useful in understanding the
common characteristics and the unique
properties of these subsets.
While genomic NFKBIA deletion seems
to be fairly common in GBM and has
a significant impact on patient prognosis,
there are several questions raised by this
report that remain unanswered. First, the
current study needs to be followed by
functional validation in vitro and in vivo.
As the level of NF-kB activity was not as-
sessed in the tumors, it remains to be
determined if NFKBIA deletion affects
the NF-kB pathway. While it is known
that glioma cell lines exhibit elevated
levels of NF-kB activity, the source of
this activation remains unclear. Addition-
ally, comparing levels of NF-kB activity
between tumors with NFKBIA deletion
and EGFR amplification will help to deter-
mine if these two mutations produce
a phenotypically similar disease. One
particular endpoint to assess would be
IL-6, a known NF-kB target gene. EGFR-
vIII, a constitutively active mutant EGFR,
has been shown to increase IL-6 levels,
which can act in a paracrine manner to
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Previewsactivate wild-type EGFR on other tumor
cells (Inda et al., 2010). One could imagine
that loss of IkBa in EGFRwild-type glioma
could increase NF-kB activity and IL-6
levels, which can further activate EGFR.
In the tumors analyzed by Bredel et al.
(2010), monoallelic, but not biallelic, loss
of NFKBIA was observed. There are
several potential interpretations of this
result, again requiring further analysis.
Loss of one copy of NFKBIA appears to
be advantageous to the tumor, possibly
for the reasons described above and/or
for other reasons. However, it seems to
be disadvantageous to lose both copies,
as it was not observed in any of the data-
sets Bredel et al. utilized. Perhaps this
speaks to the need to retain some degree
of control and inducibility over the NF-kB
pathway (Figure 1). Another possibility is
that IkBa has roles besides its most
well-studied function as an NF-kB inhib-
itor and this is critical for oncogenesis or
survival of cells of this particular lineage.
Deletions of NFKBIA in glioblastomas
reported by Bredel et al. (2010) add tothe documented mutations in the NF-kB
pathway. Given the percentage of tumors
with NFKBIA deletion and the impact on
patient survival, this event seems to be
significantly involved in glioblastoma
development, potentially providing new
targets for therapy. Future work requires
further analysis of the downstream
effects, particularly on the NF-kB
pathway. Comparison ofNFKBIA-deleted
and EGFR-amplified tumors will be impor-
tant in determining whether these two
alterations lead to a common phenotype
or if they characterize two distinct subsets
of glioblastoma. Potentially, the implica-
tion is that NF-kB signaling could be
centrally involved in all gliomas, although
the mutations responsible may vary
between subsets.REFERENCES
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A recent article in the New England Journal of Medicine by O’Shaughnessy et al. provides evidence that
a treatment strategy aimed at inducing DNA damage with chemotherapy while simultaneously disabling
repair using a PARP inhibitor might offer hope for patients with a treatment-refractory form of breast cancer.Many key genes inactivated in human
cancer are involved in DNA damage and
repair responses. Thus, specific DNA
repair defects in tumor cells might be tar-
geted selectively for therapeutic benefit
in otherwise resistant malignancies. The
emerging use of poly(ADP-ribose) poly-
merase (PARP) inhibitors in certain DNA
repair-deficient cancers promises to fulfill
this paradigm. Joyce O’Shaughnessy
and colleagues recently demonstrated
that treating patients with advanced‘‘triple-negative’’ breast cancers using
the PARP inhibitor iniparib in combination
with DNA-damaging chemotherapy in-
creased tumor responses and prolonged
patient survival compared with chemo-
therapy treatment alone (O’Shaughnessy
et al., 2011). Like many important clinical
advances however, this study leaves
many unresolved questions, and address-
ing these will be critical to realizing the
substantial promise of PARP inhibitors in
cancer therapy.PARPs catalyze the NAD+-dependent
addition of poly(ADP-ribose) units to tar-
get proteins and regulate diverse cellular
processes (Krishnakumar and Kraus,
2010). Most cellular PARP activity is
attributable to PARP1, a ubiquitous and
abundant nuclear protein that localizes
to sites of DNA damage, leading to the
recruitment of DNA repair proteins. Both
PARP1 and PARP2 have been linked to
base-excision repair, and Parp1 null
mice exhibit defective single-strandFebruary 15, 2011 ª2011 Elsevier Inc. 165
